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Rhabdomyolysis is a condition in which skeletal muscle breakdown causes the release of 
intracellular components into the bloodstream – defined as elevations in serum creatine kinase 
levels. The etiology of rhabdomyolysis is varied and may be the result of toxin-mediated mechanisms 
or metabolic derangements, or they may develop secondary to other conditions such as seizures, 
trauma and prolonged immobilization. In this case, we present a patient with suspected acute toxin-
mediated rhabdomyolysis in the setting of trimethoprim-sulfamethoxazole (TMP-SMX) therapy for 
urinary tract infection. To our knowledge, this marks the fifth case report of an otherwise healthy 
patient diagnosed with rhabdomyolysis thought to be secondary to TMP-SMX. [Clin Pract Cases 
Emerg Med. 2019;3(4):357–360.]  
INTRODUCTION 
While not an uncommon diagnosis in the emergency 
department, rhabdomyolysis is often difficult to diagnose 
clinically and may present in a variety of contexts and 
clinical scenarios. Patients often present with non-
specific generalized myalgias, aches, fatigue, urine color 
changes, and/or fevers. Others present without symptoms. 
Rhabdomyolysis presents on a spectrum from asymptomatic 
elevations in serum creatine kinase (CK) to life-threatening 
acute electrolyte disturbances requiring hemodialysis.1-2 
Identification of rhabdomyolysis usually begins in the 
proper clinical context based on history and physical, a 
suspected mechanism, and elevations in CK detected on 
laboratory analysis. Although an elevation of CK levels at 
least five-fold greater than the upper limit of normal is a 
commonly accepted parameter for definitive diagnosis, no 
true consensus exists.3-4 The etiology of rhabdomyolysis is 
varied; it may be the result of pharmacologic or biologic 
toxin-mediated mechanisms, or metabolic derangements, 
or it may develop secondary to other conditions such as 
seizures, trauma, and prolonged immobilization.1-3 When 
considering the precipitating mechanism, it is helpful 
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to consider four main categories: ischemic, pharmacologic, 
physical, and biologic.1 Commonly cited medications with a 
known association with rhabdomyolysis include statins and 
fibrates. Recreational drugs, psychiatric mediations, and a 
variety of antimicrobial agents have also been associated with 
acute rhabdomyolysis.1,2,5 
In this case, we present a patient with suspected acute toxin-
mediated rhabdomyolysis in the setting of new trimethoprim-
sulfamethoxazole (TMP-SMX) therapy for urinary tract 
infection (UTI). While rhabdomyolysis in the setting of TMP-
SMX has been well described in the immunocompromised, 
no widespread association exists with immunocompetent 
patients. To our knowledge, this marks the fifth case report of 
an otherwise healthy, immunocompetent patient diagnosed with 
rhabdomyolysis thought secondary to TMP-SMX with no other 
clear insult or mechanism to explain elevations in CK levels. 
CASE REPORT 
A 41-year-old African American male with a past medical 
history of overactive bladder, benign prostatic hyperplasia, 
obstructive sleep apnea requiring nocturnal home continuous 
positive airway pressure, presented to the emergency department 
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What do we already know about this clinical 
entity? 
Rhabdomyolysis may develop secondary to 
metabolic derangements, seizures, trauma, 
or prolonged immobilization, or via a toxin-
mediated mechanism.
What makes this presentation of disease 
reportable? 
We present a case of trimethoprim-
sulfamethoxazole (TMP-SMX) induced 
rhabdomyolysis in an otherwise healthy patient.
What is the major learning point? 
In otherwise unclear etiologies of 
rhabdomyolysis in applicable patients, recent 
TMP-SMX use should be considered as a 
possible precipitating insult. 
How might this improve emergency medicine 
practice? 
Early recognition of this possible emerging 
association between TMP-SMX and 
rhabdomyolysis in immunocompetent patients 
may alter emergency department management 
and treatment.
(ED) with a chief complaint of increasing proximal bilateral 
lower extremity muscle pain for five days. Pain was associated 
with increasing difficulty with ambulation. The patient also 
noted persisting hematuria, urgency and hesitancy for the prior 
nine days. He had fever to 101.2° Fahrenheit (F) for the prior 
five days. Symptoms were associated with intermittent episodes 
of nausea and vomiting for the prior two days. Four days prior 
to presentation, the patient reported having seen his outpatient 
urologist who diagnosed a UTI. He was prescribed TMP-SMX 
double strength 160 milligrams (mg)/800mg. and endorsed 
medication compliance. 
On ED arrival, the patient was found to be febrile to 102.3°F 
and hemodynamically stable. On exam, he appeared grossly 
uncomfortable. The bilateral lower extremity proximal muscle 
strength was 4/5 without point tenderness. There was no evidence 
of lower extremity edema, erythema or rash. Distal pulses were 
intact. The patient was also noted to have mild left lower quadrant 
abdominal and suprapubic tenderness to palpation; there was no 
costovertebral angle tenderness to palpation. Physical exam was 
otherwise unremarkable. 
Initial laboratory analysis showed an aspartate transaminase 
(AST) 274 units per liter (u/L) (reference range, 4-40 u/L), 
alanine transaminase (ALT) 102 u/L (reference range, 4-41 
u/L), CK muscle/brain 3.11 nanograms per milliliter (ng/
mL) (reference range, 1-6.6 ng/mL) with a CK 60,665 ng/mL 
(reference range, 30-200 u/L). Labs obtained from the patient’s 
outpatient urologist from four days prior to presentation showed 
an initial leukocytosis to 14.4 103 per cubic millimeter (mm3), 
which resolved prior to ED arrival, a urine analysis consistent 
with UTI: positive large blood with greater than 50 red blood 
cells per high-powered field, 50 white blood cells per high-
powered field, and positive leukocyte esterase. A urine culture 
was positive for Escherichia coli sensitive to TMP-SMX per the 
outpatient urologist. The outpatient provider did not request CK 
levels at initial visit, but at that time AST/ALT levels were 22 u/L 
and 30 u/L, respectively. 
Chest radiograph and computed tomography of the abdomen 
and pelvis in the ED were negative for acute pulmonary or intra-
abdominal pathologies. In the ED, the patient received one gram 
of ceftriaxone for UTI, two liters of normal saline, acetaminophen 
for fever, and morphine for pain control. TMP-SMX was 
discontinued. He was admitted to the inpatient internal medicine 
service with a concern for non-traumatic acute rhabdomyolysis 
and pyelonephritis. Further workup by the inpatient medicine 
team excluded other possible causes for acute rhabdomyolysis. 
Respiratory viral panel and human immunodeficiency virus 
studies were negative. Urine toxicology was positive for opiates. 
Epstein-Barr viral studies were consistent with a prior infection 
with immunity. Thyroid and glucose-6-phosphate dehydrogenase 
studies were normal. CK and AST levels peaked on days two and 
three of admission, respectively (Figure). 
The patient continued to receive intravenous and oral fluids 
as well as pain control. Over the eight days of admission the 
patient continued to improve. He reported decreasing muscle pain 
and was increasingly able to ambulate without difficulty. During 
the course of his hospital stay, the patient sustained no electrolyte 
abnormalities, and creatinine and blood urea nitrogen were within 
normal limits. There was no evidence of acute kidney injury. The 
patient was discharged on day eight with resolution of symptoms 
and a down-trending of CK and AST/ALT.  
DISCUSSION
Trimethoprim-sulfamethoxazole is a bacterial folic 
acid synthesis inhibitor used to treat a variety of conditions 
including UTI, skin and soft tissue infections in healthy 
patients, and pneumocystis pneumonia or toxoplasmosis in 
the immunocompromised patient. Side effects generally are 
mild and include rash, fever, muscle aches and diarrhea. TMP-
SMX is also known to have an association with more severe 
side effects including Steven-Johnson syndrome and toxic 
epidermal necrolysis, although these are quite rare.6 TMP-SMX 
induced rhabdomyolysis is more often seen in the setting of 
immunocompromised patients or in the setting of allogeneic stem 
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Figure. Creatinine kinase (CK), aspartate transaminase (AST) and alanine transaminase (ALT) trends during admission.
300,000
250,000
200,000
150,000
100,000
50,000
0
0 1
60,665
205,006
279,140 279,140
184,667
94,109
39,387
26,603
10,798
83 4 5 6 72 0 1 3 4 5 6 72
0
200
400
600
800
1,000
1,200
1,400
C
K
 le
ve
l, 
u/
L
A
S
T/
A
LT
 IU
/L
102 139
250
357 415
247
262
158
195274
480
1011
1232
1092
AST
ALT
cell transplant recipients.7-8 To our knowledge, this report now 
represents the fifth case of TMP-SMX induced rhabdomyolysis 
in the setting of an otherwise healthy, immunocompetent patient. 
In 2014 Ainapurapu et al. reported a case of a previously 
healthy 40-year-old Hispanic female. She initially presented with 
two days of bilateral lower extremity muscle aches and weakness. 
She reported she was prescribed TMP-SMX for a UTI two days 
prior and had taken four doses. She presented with an initial 
CK of 20063 u/L, with an otherwise negative workup for other 
etiologies explaining her rhabdomyolysis.8 
A second case in 2015 by Petrov et al. was that of a 64-year-
old male, active smoker, who also presented complaining of 
bilateral lower extremity pain and a decreasing ability to ambulate 
secondary to discomfort. The patient reported self-treating a 
presumed UTI with TMP-SMX left over from a prior episode of 
UTI. He reported taking TMP-SMX 40mg/800mg three times 
a day for two weeks. On first presentation to the ED, the patient 
was found to have a CK of 1524 u/L, and he was referred to a 
neurologist with suspicion for polymyositis. TMP-SMX was 
not discontinued and the patient’s pain continued to worsen. The 
patient also was prescribed ibuprofen, celecoxib, piroxicam, 
ketorolac, and meloxicam. On subsequent presentations to 
the ED, the patient was found to have a CK of 614,691 u/L, 
elevated transaminases, and multiple electrolyte derangements. 
Muscle biopsy was suggestive of muscle fibers without striations 
and a loss of homogeneity. Other causes of rhabdomyolysis 
were ruled out. TMP-SMX was discontinued, and over the 
course of admission the patient reported improvement in all 
symptomatology and was subsequently discharged.9 
In 2017, Moye et al. presented a case of a 43-year-old 
African American female with a past medical history of 
depression and alcohol-use disorder who presented to the ED 
after eight days of bilateral lower extremity leg pain in the 
setting of taking five doses of TMP-SMX 160mg/800mg for a 
UTI. She reported a history of daily alcohol consumption and 
10mg vortioxetine. She first began to experience leg pain two 
days after initiation of TMP-SMX when she re-presented to her 
primary care provider. There she was switched to ciprofloxacin. 
The patient continued to experience worsening leg pain, which 
prompted her visit to the ED. There she was found to have a CK 
of 26,231 u/L with elevated transaminases AST/ALT of 352/111 
u/L, respectively.10 She was admitted, started on intravenous (IV) 
fluids and folic acid supplementation. During her admission, 
CK peaked at 45,020 u/L without increase in serum creatinine. 
She was discharged on day eight after improvement in her lower 
extremity discomfort and with a CK of 2809 u/L. 
Also in 2017, Goyal et al. presented a case of an 18-year-old 
female with a past medical history of Arnold-Chiari malformation 
presenting from her primary care provider (PCP) complaining of 
severe weakness and diffuse muscle pains in all extremities for 
two days. She endorsed recent completion of a course of TMP-
SMX for UTI from her PCP. At time of admission, she was noted 
to have severe proximal muscle weakness in all four extremities 
and diffuse muscle tenderness. On admission her CK level was 
20,418 u/L, which peaked the next day to greater than 42,670 
u/L, the maximal quantifiable limit per the institution’s laboratory. 
She initially received aggressive fluid resuscitation without 
improvement. Ultimately, she was started on IV immunoglobulin 
G with eventual resolution of elevations in CK. 
There are a few concerning similarities with each of 
these presentations. In each case TMP-SMX was initiated 
for a presumed UTI. Subsequently, each patient presented 
complaining of bilateral lower extremity proximal muscle 
weakness or pain. Each case demonstrated elevations in CK 
consistent with rhabdomyolysis. TMP-SMX was discontinued 
resulting in improvement of clinical status and resolution 
of CK levels. Each patient had a negative workup for other 
etiologies of rhabdomyolysis and was without concern for 
immunocompromised state. 
There are certainly possible confounding factors in each 
patient presentation. Confounders include but are not limited 
to pre-existing medical conditions and past medical history, 
Days Days
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outpatient prescription medications, home self-medication, 
substance abuse and non-modifiable factors including gender 
and age. However, the overarching consistencies – indication 
for therapy, the temporal relationship to initiation of TMP-SMX 
therapy, and chief complaint at presentation – are noteworthy 
and are fairly consistent between cases. 
CONCLUSION 
After evaluating for and eliminating other possible 
toxic, biologic or physical and traumatic etiologies of acute 
rhabdomyolysis in our patient, we concluded that TMP-SMX was 
the most likely insulting agent. Furthermore, while serum CK 
was not obtained prior to initiation of TMP-SMX, the temporal 
relationship of normal AST four days prior to presentation – and 
parallel trending of AST/ALT with CK at time of presentation and 
during admission– suggests that our patient’s rising AST/ALT was 
likely secondary to skeletal muscle breakdown and may serve as 
a surrogate for CK. TMP-SMX was discontinued and over the 
course of admission the CK, proximal lower extremity myalgia, 
ability to ambulate, and overall clinical status gradually improved. 
In each of the four prior cases, as with ours, the indication 
for TMP-SMX therapy was a UTI. Our case report adds to 
a growing body of anecdotal evidence that suggests TMP-
SMX may be associated with acute rhabdomyolysis in 
immunocompetent patients. While the authors are not aware of 
any large, multicenter study evaluating for a true association of 
TMP-SMX with rhabdomyolysis, additional larger scale studies 
are warranted. Providers should be made aware of this possible 
emerging association between TMP-SMX and rhabdomyolysis in 
immunocompetent patients. 
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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